Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) hit a new 52-week low on Wednesday . The company traded as low as $9.48 and last traded at $9.59, with a volume of 536323 shares changing hands. The stock had previously closed at $9.99. Wall Street Analyst Weigh In A number of research firms recently weighed […]
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) hit a new 52-week low on Wednesday . The company traded as low as $9.48 and last traded at $9.59, with a volume of 536323 shares changing hands. The stock had previously closed at $9.99. Wall Street Analyst Weigh In A number of research firms recently weighed […]
04.06.2024 - NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) - Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental .
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the transaction, the chief financial officer now owns 633,680 shares in the company, […]
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the sale, the chief financial officer now owns 633,680 shares in the company, […]